HIV-associated psoriasis

AIDS Patient Care and STDs

Volumn 14, Issue 5, 2000, Pages 239-246

  Mallon, E ^a   Bunker, C B ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CD4 ANTIGEN; CD8 ANTIGEN; COTRIMOXAZOLE; CYCLOSPORIN; DITHRANOL; ETRETIN; METHOTREXATE; RITONAVIR; ZALCITABINE; ZIDOVUDINE;

ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; DRUG HYPERSENSITIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; PATHOGENESIS; PHOTOTHERAPY; PREVALENCE; PROGNOSIS; PSORIASIS;

HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; PSORIASIS;

EID: 0034074071     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729100317696     Document Type: Article

References (45)

1. Camp RDR. In: Champion RH, Burton JL, Burns DA, Breathnach SM (eds). Textbook of Dermatology, Vol 2 (6th ed.) Oxford: Blackwell Science, 1998:1589-649.
2. Van de Kerkhof PCM, Bos JD (eds). Pathogenic aspects of psoriasis. Clin Dermatol 1995;13:97-190.
3. Bellamy N. Seronegative spondyloarthropathies. In: Colour Atlas of Rheumatology. Lancaster: MTP press, 1985, pp 81-93.
4. Leczinsky CG. The incidence of arthropathy in a tenyear series of psoriasis cases. Acta Derm Venereol 1948;28:483-487.
5. Duvic M, Johnson TM, Rapini RP, Freese T, Brewton G, Rios A. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol 1987;123:1622-1632.
6. Kaplan MH, Sadick NS, Wieder J, Farber BF, Neidt GW. Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis. J Am Acad Dermatol 1989;20:76-82.
7. Uthayakumar S, Nandwani R, Drinkwater T, Nayagama MA, Darley C. The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol 1997;137:595-598.
8. Garbe C, Husak R, Orfanos CE. HIV associated dermatoses and their prevalence in 456 HIV infected individuals. Relation to immunological status and diagnostic significance. Hautartz 1994;45:623-629.
9. Berman A, Espinoza LR, Diaz JD. Rheumatic manifestations of human immunodeficiency virus infection. Am J Med 1988;85:59-64.
10. Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriasis arthritis, and Reiter's syndrome: A disease continuum? Arthritis Rheum 1990;33:1574-1578.
11. Winchester R. Psoriatic arthritis. Dermatol Clin 1995;13:779-792.
12. Michet CJ, Machado EBV, Ballard DJ. Epidemiology of Reiter's syndrome in Rochester, Minnesota: 1950-1980. Arthritis Rheum 1988;31:428-431.
13. Elder JT, Nair RP, Guo S-W, Hensler T, Christophers E, Voorhees J. The genetics of psoriasis. Arch Dermatol 1994;130:216-224.
14. Mallon E, Bunce M, Welsh K, Wojnarowska F. HLA-Cw*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type 1 psoriatics. J Invest Dermatol 1997;109:183-186.
15. Mallon E, Bunce M, Savoie H, Gotch F, Bunker CB. HLA-Cw*0602 and guttate psoriasis. J Invest Dermatol 1998;110:618.
16. Mallon E, Young D, Bunce M, Gotch FM, Easterbrook PJ, Newson R, Bunker CB. HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol 1998;139:527-533.
17. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genetics 1997;6:813-820.
18. Schendel D, Reinhardt C, Necson P, et al. Cytotoxic T lymphocytes show recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self peptides. J Immunol 1992;149:2406-2414.
19. Harrer T, Harrer E, Kalams S, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. J Immunol 1996;156:2616-2623.
20. Johnson RP, Trocha A, Buchanan T, Walker B. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4 restricted cytotoxic T lymphocyte clone. J Virol 1993;67:438-445.
21. Asahina A, Akazaki S, Nakagawa H, et al. Specific nucleotide sequence of HLA-C is strongly associated with psoriasis vulgaris. J Invest Dermatol 1991;97:254-258.
22. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen HLA-A2. Nature 1987;329:506-512.
23. Placek W, Haftek M, Thivolet J. Sequence of changes in psoriatic epidermis. Immunocompetent cell redistribution precedes altered expression of keratinocyte differentiation markers. Acta Derm Venereol (Stockh) 1988;68:369-372.
24. Ramirez-Bosca M, Martinez-Ojeda L, ValcuendeCavero F, et al. A study of local immunity in psoriasis. Br J Dermatol 1989;119:587-595.
25. Parent D, Bernard BA, Desbas C, Heenen M, Darmon MY. Spreading of psoriatic plaques: Alteration of epidermal differentiation prcedes capillary leakiness and anomalies in vascular morphology. J Invest Dermatol 1991;96:529-530.
26. Chang JC, Smith LR, Froning KJ, et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/or Vβ3 13.1 genes. Proc Natl Acad Sci USA 1994;91:9282-9286.
27. Leung DY, Travers J, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 1995a;96:2106-2112.
28. Bunker CB. Dermatological problems in HIV infection and AIDS. In: Millar A, ed. Medical Management of HIV and AIDS. Berlin: Springer-Verlag, 1996, pp. 162-189.
29. Vogel J, Hinrichs S, Reynolds R, Luciw P, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988;335:606-612.
30. Leonard JM, Abramczuk JW, Pezen DS, et al. Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science 1988;242:1665-1670.
31. Lewis HM, Baker BS, Bokth S, et al. Restricted T-cell receptor Vβ gene usage in the skin of patients with guttate and chronic plaque psoriasis. Br J Dermatol 1993;129:514-520.
32. McFadden J, Valdimarsson H, Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol 1991;125:343-347.
33. Obuch ML, Maurer TA, Becker B, Berger TG. Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol 1992;27:667-673.
34. Colebunders R, Blot K, Meriens V, Dock P. Psoriasis regression in terminal AIDS. Lancet 1992;339:1110.
35. Jaffe D, May LP, Sanchez M, Moy J. Staphylococcal sepsis in HIV antibody seropositive psoriasis patients. J Am Acad Dermatol 1991;24:970-972.
36. King LE, Dufresne RG, Lovett GL. Erythroderma: Review of 82 cases. South Med J 1986;79:1210-1215.
37. Arnett FC, Reveille JD, Duvic M. Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection. Rheum Dis Clin North Am 1991;17:59-78.
38. Wilkens RF, Arnett FC, Bitter T. Reiter's syndrome: Evaluation of preliminary criteria for definite disease. Arthritis Rheum 1981;24:844-849.
39. McKee PH. Psoriasis. In: Pathology of the Skin with Clinical Correlations, 2nd ed. London: Mosby-Wolfe, 1996, pp. 8.1-8.8.
40. Horn TD, Herzberg G, Hood AF. Characterization of the dermal infiltrate in human immunodeficiency virus-infected patients with psoriasis. Arch Dermatol 1990;125:1462-1465.
41. Houpt KR, Beer JZ, Horn TD, Moy ZA, Zmudzka BZ, Cruz PD. Ultraviolet therapy of HIV-infected individuals: a panel discussion. Semin Cutan Med Surg 1997;16:241-245.
42. Allen BR. Use of cyclosporin for psoriasis in HIV positive patient. Lancet 1992;339:686.
43. Maurer TA, Zackheim HS, Taffanelli L, Berger TG. The use of methotrexate for the treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994;31:372-375.
44. Townsend BL, Cohen PR, Duvic M. Zidovudine for the treatment of HIV negative patients with soriasis: A pilot study. J Am Acad Dermatol 1995;32:994-999.
45. Bunker C, Staughton R. Dermatology. In: Gazzard B, ed. Chelsea & Westminster Hospital AIDS Care Handbook. London: Mediscript Ltd Medical Publishers, 1999, pp. 113-136.